Top

Published in:

01-12-2014 | Original paper

Urinary bisphenol A-glucuronide and postmenopausal breast cancer in Poland

Authors: Britton Trabert, Roni T. Falk, Jonine D. Figueroa, Barry I. Graubard, Montserrat Garcia-Closas, Jolanta Lissowska, Beata Peplonska, Stephen D. Fox, Louise A. Brinton

Published in: Cancer Causes & Control | Issue 12/2014

Abstract

Purpose

Concerns regarding a possible link between bisphenol A (BPA) and breast cancer have been mounting, but studies in human populations are lacking. We evaluated the association between the major urinary BPA metabolite [BPA-glucuronide (BPA-G)] and postmenopausal breast cancer risk in a large population-based case–control study conducted in two cities in Poland (2000–2003); we further explored the association of BPA-G levels with known postmenopausal breast cancer risk factors in our control population.

Methods

We analyzed creatinine-adjusted urinary BPA-G levels among 575 postmenopausal cases matched on age and study site to 575 controls without breast cancer using a recently developed assay. Odds ratios and 95 % confidence intervals were used to estimate the association between urinary BPA-G level and breast cancer using conditional logistic regression. Among controls, geometric mean BPA-G levels were compared across categories of breast cancer risk factors using linear regression models.

Results

There was no indication that increased BPA-G was associated with postmenopausal breast cancer (p-trend = 0.59). Among controls, mean BPA-G was higher among women reporting extended use of menopausal hormones, a prior screening mammogram, and residence in Warsaw. Other comparisons across strata of postmenopausal breast cancer risk factors were not related to differences in BPA-G.

Conclusions

Urinary BPA-G, measured at the time of diagnosis, is not linked to postmenopausal breast cancer.

Available only for authorised users

Talsness CE, Andrade AJ, Kuriyama SN, Taylor JA, vom Saal FS (2009) Components of plastic: experimental studies in animals and relevance for human health. Philos Trans R Soc Lond B Biol Sci 364(1526):2079–2096. doi:10.1098/rstb.2008.0281 PubMedCentralPubMedCrossRef

Stahlhut RW, Welshons WV, Swan SH (2009) Bisphenol A data in NHANES suggest longer than expected half-life, substantial nonfood exposure, or both. Environ Health Perspect 117(5):784–789. doi:10.1289/ehp.0800376 PubMedCentralPubMedCrossRef

Durando M, Kass L, Perdomo V, Bosquiazzo VL, Luque EH, Munoz-de-Toro M (2011) Prenatal exposure to bisphenol A promotes angiogenesis and alters steroid-mediated responses in the mammary glands of cycling rats. J Steroid Biochem Mol Biol 127(1–2):35–43. doi:10.1016/j.jsbmb.2011.04.001 PubMedCrossRef

Durando M, Kass L, Piva J et al (2007) Prenatal bisphenol A exposure induces preneoplastic lesions in the mammary gland in Wistar rats. Environ Health Perspect 115(1):80–86PubMedCentralPubMedCrossRef

Tharp AP, Maffini MV, Hunt PA, Vandevoort CA, Sonnenschein C, Soto AM (2012) Bisphenol A alters the development of the rhesus monkey mammary gland. Proc Natl Acad Sci USA 109(21):8190–8195. doi:10.1073/pnas.1120488109 PubMedCentralPubMedCrossRef

Dairkee SH, Seok J, Champion S et al (2008) Bisphenol A induces a profile of tumor aggressiveness in high-risk cells from breast cancer patients. Cancer Res 68(7):2076–2080. doi:10.1158/0008-5472 PubMedCrossRef

Recchia AG, Vivacqua A, Gabriele S et al (2004) Xenoestrogens and the induction of proliferative effects in breast cancer cells via direct activation of oestrogen receptor alpha. Food Addit Contam 21(2):134–144. doi:10.1080/02652030310001641177 PubMedCrossRef

Vivacqua A, Recchia AG, Fasanella G et al (2003) The food contaminants bisphenol A and 4-nonylphenol act as agonists for estrogen receptor alpha in MCF7 breast cancer cells. Endocrine 22(3):275–284. doi:10.1385/ENDO:22:3:275 PubMedCrossRef

Calafat AM, Kuklenyik Z, Reidy JA, Caudill SP, Ekong J, Needham LL (2005) Urinary concentrations of bisphenol A and 4-nonylphenol in a human reference population. Environ Health Perspect 113(4):391–395PubMedCentralPubMedCrossRef

10.

Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL (2008) Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003–2004. Environ Health Perspect 116(1):39–44. doi:10.1289/ehp.10753 PubMedCentralPubMedCrossRef

11.

Vandenberg LN, Hauser R, Marcus M, Olea N, Welshons WV (2007) Human exposure to bisphenol A (BPA). Reprod Toxicol 24(2):139–177. doi:10.1016/j.reprotox.2007.07.010 PubMedCrossRef

12.

Melzer D, Rice NE, Lewis C, Henley WE, Galloway TS (2010) Association of urinary bisphenol a concentration with heart disease: evidence from NHANES 2003/06. PLoS One 5(1):e8673. doi:10.1371/journal.pone.0008673 PubMedCentralPubMedCrossRef

13.

Carwile JL, Michels KB (2011) Urinary bisphenol A and obesity: NHANES 2003–2006. Environ Res 111(6):825–830. doi:10.1016/j.envres.2011.05.014 PubMedCentralPubMedCrossRef

14.

Yang M, Ryu JH, Jeon R, Kang D, Yoo KY (2009) Effects of bisphenol A on breast cancer and its risk factors. Arch Toxicol 83(3):281–285. doi:10.1007/s00204-008-0364-0 PubMedCrossRef

15.

Volkel W, Colnot T, Csanady GA, Filser JG, Dekant W (2002) Metabolism and kinetics of bisphenol a in humans at low doses following oral administration. Chem Res Toxicol 15(10):1281–1287PubMedCrossRef

16.

Garcia-Closas M, Brinton LA, Lissowska J et al (2006) Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer 95(1):123–129. doi:10.1038/sj.bjc.6603207 PubMedCentralPubMedCrossRef

17.

Fox SD, Falk RT, Veenstra TD, Issaq HJ (2011) Quantitation of free and total bisphenol A in human urine using liquid chromatography-tandem mass spectrometry. J Sep Sci 34(11):1268–1274. doi:10.1002/jssc.201100087 PubMedCrossRef

18.

Nachman RM, Fox SD, Golden WC et al (2013) Urinary free bisphenol A and bisphenol A-glucuronide concentrations in newborns. J Pediatr 162(4):870–872. doi:10.1016/j.jpeds.2012.11.083 PubMedCentralPubMedCrossRef

19.

Calafat AM, Koch HM, Swan SH et al (2013) Misuse of blood serum to assess exposure to bisphenol A and phthalates. Breast Cancer Res 15(5):403. doi:10.1186/bcr3494 PubMedCentralPubMedCrossRef

20.

Harthe C, Rinaldi S, Achaintre D et al (2012) Bisphenol A-glucuronide measurement in urine samples. Talanta 100:410–413. doi:10.1016/j.talanta.2012.07.099 PubMedCrossRef

21.

Lang IA, Galloway TS, Scarlett A et al (2008) Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA 300(11):1303–1310. doi:10.1001/jama.300.11.1303 PubMedCrossRef

22.

Melzer D, Osborne NJ, Henley WE et al (2012) Urinary bisphenol A concentration and risk of future coronary artery disease in apparently healthy men and women. Circulation 125(12):1482–1490. doi:10.1161/CIRCULATIONAHA.111.069153 PubMedCrossRef

23.

Wang T, Li M, Chen B et al (2012) Urinary bisphenol A (BPA) concentration associates with obesity and insulin resistance. J Clin Endocrinol Metab 97(2):E223–E227. doi:10.1210/jc.2011-1989 PubMedCrossRef

24.

Sprague BL, Trentham-Dietz A, Hedman CJ et al (2013) Circulating serum xenoestrogens and mammographic breast density. Breast Cancer Res 15(3):R45. doi:10.1186/bcr3432 PubMedCentralPubMedCrossRef

25.

Townsend MK, Franke AA, Li X et al (2013) Within-person reproducibility of urinary bisphenol A and phthalate metabolites over a 1–3 year period among women in the Nurses’ Health Studies: a prospective cohort study. Environ Health 12(1):80. doi:10.1186/1476-069X-12-80 PubMedCentralPubMedCrossRef

26.

Braun JM, Kalkbrenner AE, Calafat AM et al (2011) Variability and predictors of urinary bisphenol A concentrations during pregnancy. Environ Health Perspect 119(10):131–137. doi:10.1289/ehp.1002366 PubMedCentralPubMed

27.

Ye X, Wong LY, Bishop AM, Calafat AM (2011) Variability of urinary concentrations of bisphenol A in spot samples, first morning voids, and 24-h collections. Environ Health Perspect 119(7):983–988. doi:10.1289/ehp.1002701 PubMedCentralPubMedCrossRef

Title: Urinary bisphenol A-glucuronide and postmenopausal breast cancer in Poland
Authors: Britton Trabert
Roni T. Falk
Jonine D. Figueroa
Barry I. Graubard
Montserrat Garcia-Closas
Jolanta Lissowska
Beata Peplonska
Stephen D. Fox
Louise A. Brinton
Publication date: 01-12-2014
Publisher: Springer International Publishing
Published in: Cancer Causes & Control / Issue 12/2014
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-014-0461-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2014

Cancer beliefs and prevention policies: comparing Canadian decision-maker and general population views

Smoking, alcohol, diabetes, obesity, socioeconomic status, and the risk of colorectal cancer in a population-based case–control study

Conization as a marker of persistent cervical human papillomavirus (HPV) infection and risk of gastrointestinal cancer: a Danish 34-year nationwide cohort study

Multiple human papillomavirus infection with or without type 16 and risk of cervical intraepithelial neoplasia among women with cervical cytological abnormalities

Cancer incidence in a cohort with high fish consumption

Intake of fruit and vegetables and risk of bladder cancer: a dose–response meta-analysis of observational studies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer